| 摘要 |
Disclosed are 2-(imidazo[1,2-a]pyridin-2-yl)pyrrolidine derivatives as represented by the general formula (I), wherein: X1 and X2 are each independently O or S; Y is CH2; Z is H, alkyl, a carbocycle or a heterocycle which may be substituted; Q is H, halogen, hydroxyl, carboxyl, amino, nitro, cyano, alkyl, a carbocycle or a heterocycle; wherein said alkyl, carbocycle and heterocycle may be substituted; R1, R3', R4', R5, R6 and R6' are each hydrogen; R2 is morpholino or cyclohexyl; R3 and R4 are methyl; R7 is H, cyano, hydroxyl, mercapto, halogen, nitro, carboxyl, amidino, guanidino, alkyl, a carbocycle, a heterocycle or -U-V; R8 is H, alkyl, a carbocycle or a heterocycle wherein one or more CH2 or CH groups of said alkyl is optionally replaced with -O-, -S-, -S(O)-, S(O)2, or -C(O)-; and said alkyl, carbocycle and heterocycle is optionally substituted; and m is 0 to 4; or a salt or stereoisomer thereof. Representative compounds include those where the 2-(imidazo[1,2-a]pyridin-2-yl)pyrrolidine moiety is substituted on the 1-position with N-methyl-L-alanine-L-cyclohexylglycine or N-methyl-L-alanine-L-morpholin-4-ylglycine. Further disclosed is a pharmaceutical composition which comprises a compound as defined above and a carrier, diluent or excipient for the treatment of cancer.
|
